Daily Respiratory Research Analysis
Analyzed 231 papers and selected 3 impactful papers.
Summary
A double-blind randomized trial showed that ensitrelvir significantly reduced COVID-19 incidence in household contacts with a safety profile similar to placebo. A multicenter RCT (OxyKids) found that targeting a lower pediatric oxygen saturation (88% vs 92%) safely reduced oxygen exposure without worsening outcomes. Translational work identified an NKG2A–HLA‑E checkpoint axis suppressing NK cell clearance of senescent fibroblasts in fibrotic lung disease, supporting NK-centered antifibrotic strategies.
Research Themes
- Antiviral postexposure prophylaxis for respiratory viruses
- Oxygen therapy targets in pediatric acute respiratory illness
- Immune checkpoint pathways in pulmonary fibrosis and NK-cell therapy
Selected Articles
1. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
In a double-blind RCT of 2041 household contacts, ensitrelvir reduced symptomatic, PCR-confirmed COVID-19 from 9.0% to 2.9% (RR 0.33) when started within 72 hours of index case symptom onset. Adverse events and serious adverse events were similar to placebo, with no COVID-19-related hospitalizations or deaths.
Impact: This trial provides the first high-quality evidence that an oral antiviral can prevent COVID-19 after household exposure, with a favorable safety profile.
Clinical Implications: Ensitrelvir can be considered for postexposure prophylaxis in household contacts, particularly within 72 hours of index symptom onset and among those at higher risk for severe disease, potentially informing guideline updates.
Key Findings
- Symptomatic, PCR-confirmed COVID-19 by day 10: 2.9% with ensitrelvir vs 9.0% with placebo (RR 0.33, 95% CI 0.22–0.49, P<0.001).
- Adverse events similar between groups (15.1% vs 15.5%) and serious adverse events 0.2% in each arm; no COVID-19 hospitalizations or deaths.
- Most participants randomized within 48 hours of index onset (71.1%); 37% had at least one risk factor for severe COVID-19.
Methodological Strengths
- Double-blind, randomized, placebo-controlled design with large mITT sample (n=2041).
- Central laboratory-confirmed RT-PCR outcomes and prespecified symptom criteria.
Limitations
- Trial conducted in a single country context, which may limit generalizability across variants and settings.
- Primary endpoint limited to day 10; longer-term outcomes and transmission effects were not assessed.
Future Directions: Evaluate real-world effectiveness across variants and vaccination statuses, assess impact on secondary transmission, and define optimal target populations and timing.
BACKGROUND: Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Covid-19. METHODS: In this double-blind, randomized, placebo-controlled trial, we randomly assigned persons who were SARS-CoV-2-negative on local diagnostic testing but were household contacts of a patient with Covid-19 (the index patient) to receive either ensitrelvir (375 mg on day 1 and 125 mg daily on days 2 through 5) or placebo within 72 hours after symptom onset in the index patient. The primary end point was Covid-19 (defined by a central laboratory-confirmed positive reverse-transcriptase-polymerase-chain-reaction assay and the presence of ≥1 of 14 prespecified Covid-19 symptoms lasting ≥48 hours) by day 10 in a household contact in the modified intention-to-treat population (all the participants who underwent randomization, had a central laboratory-confirmed negative RT-PCR test for SARS-CoV-2 at baseline, and received at least one dose of the trial drug or placebo). RESULTS: The modified intention-to-treat population included 1030 participants in the ensitrelvir group and 1011 in the placebo group. The mean age of the participants was 42.4 years; 71.1% had undergone randomization within 48 hours after symptom onset in the index patient, and 37.0% had at least one risk factor for severe Covid-19. The incidence of Covid-19 was lower in the ensitrelvir group than in the placebo group (2.9% vs. 9.0%; risk ratio, 0.33; 95% confidence interval [CI], 0.22 to 0.49; P<0.001). The incidence of adverse events during the trial was similar in the two groups (15.1% in the ensitrelvir group and 15.5% in the placebo group), as was the incidence of serious adverse events (0.2% in each group). No Covid-19-related hospitalizations or deaths were reported. CONCLUSIONS: Ensitrelvir administered to household contacts of a patient with Covid-19 within 72 hours after symptom onset in the index patient was effective in preventing Covid-19 in the contacts. (Funded by Shionogi; SCORPIO-PEP Japan Registry for Clinical Trials number, jRCT2031230124; ClinicalTrials.gov number, NCT05897541.).
2. Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Single-cell and functional studies identify an HLA‑E–NKG2A checkpoint axis by which senescent fibroblasts suppress NK cells in fibrotic lungs. Targeting this pathway restores antifibrotic NK activity and supports NK cell–based immunotherapy to reverse fibrosis.
Impact: Reveals a druggable immune checkpoint axis driving persistence of fibrotic stroma and provides a mechanistic rationale for NK-directed antifibrotic immunotherapy.
Clinical Implications: Supports clinical exploration of NKG2A blockade and NK cell–based therapies in pulmonary fibrosis, with HLA‑E/NKG2A as biomarkers for patient stratification.
Key Findings
- NKG2A is the predominant inhibitory checkpoint receptor on NK cells in fibrotic lung disease (scRNA-seq and spectral flow cytometry).
- Senescent fibroblasts express HLA‑E, suppressing NK function via HLA‑E–NKG2A interactions in mechanistic coculture assays.
- In IPF lungs, scRNA-seq identified selective HLA‑E expression in senescent HAS1-associated fibroblasts, implicating targeted immune evasion.
Methodological Strengths
- Multi-omic approach combining scRNA-seq with high-dimensional flow cytometry in human fibrotic lungs.
- Mechanistic validation via in vitro coculture demonstrating checkpoint-mediated NK suppression.
Limitations
- Abstracted data do not detail in vivo reversal magnitude or clinical outcomes.
- Sample sizes and heterogeneity across fibrotic etiologies are not specified here.
Future Directions: Translate NKG2A blockade and NK adoptive strategies into early-phase trials in IPF; develop companion diagnostics for HLA‑E/NKG2A; assess synergy with antifibrotic drugs.
Impaired immune clearance of senescent fibroblasts is a putative driver of pulmonary fibrosis. Exhausted natural killer (NK) cells have been implicated in this process, yet the underlying immune evasion mechanisms remain poorly understood. Using single-cell RNA sequencing (scRNA-seq) and spectral flow cytometry, we identified natural killer group 2 member A (NKG2A) as the predominant inhibitory checkpoint receptor expressed on NK cells in fibrotic lung diseases. Mechanistic in vitro coculture studies showed that NK cell suppression was mediated by senescent fibroblasts expressing human leukocyte antigen-E (HLA-E), the high-affinity ligand for NKG2A. scRNA-seq analysis of lungs from patients with idiopathic pulmonary fibrosis (IPF) further identified selective HLA-E expression in senescent HAS1
3. Oxygen saturation thresholds in children with acute respiratory distress (OxyKids): a multicentre, open, parallel-group, randomised clinical trial.
In this pragmatic multicenter RCT (n=566), targeting an SpO2 of 88% versus 92% in children needing oxygen for bronchiolitis, lower respiratory tract infection, or viral wheeze was safe and reduced oxygen exposure without worsening clinical outcomes.
Impact: Challenges long-standing higher oxygen saturation targets and supports safer, more resource-efficient oxygen strategies in pediatric acute respiratory care.
Clinical Implications: Hospitals may consider adopting an SpO2 target of 88% (instead of 92%) for select pediatric acute respiratory conditions to reduce oxygen exposure and resource use without compromising safety.
Key Findings
- Randomized 566 children to SpO2 88% vs 92% targets across 10 hospitals in the Netherlands.
- Lower target (88%) safely reduced oxygen exposure; no signals of harm or worse clinical outcomes were observed.
- Pragmatic, multicenter design across bronchiolitis, LRTI, and viral-induced wheeze enhances generalizability within similar care settings.
Methodological Strengths
- Multicenter randomized design with stratification by center and age group.
- Pragmatic clinical endpoints relevant to oxygen exposure and safety.
Limitations
- Open-label design may introduce performance bias in oxygen weaning decisions.
- Conducted within a single national health system, which may limit global generalizability.
Future Directions: Quantify effects on hospital length of stay, readmissions, and caregiver-centered outcomes; assess applicability in resource-limited settings and with different monitoring technologies.
BACKGROUND: Current peripheral oxygen saturation (SpO METHODS: We did a multicentre, open-label, randomised controlled trial in ten general and teaching hospitals in the Netherlands. Children (aged 6 weeks-12 years) requiring oxygen therapy for bronchiolitis, lower respiratory tract infection, or acute viral-induced wheeze were randomly assigned (1:1), stratified by centre and age group, to an 88% (intervention) or 92% (control) SpO FINDINGS: Between Sep 5, 2023, and Dec 4, 2024, 2114 patients were assessed for eligibility, 512 were excluded (425 did not meet inclusion criteria and 87 did not require oxygen therapy) and 1602 met the inclusion criteria. A further 1036 patients were excluded and 566 were randomly assigned (282 to the 88% SpO INTERPRETATION: Our findings suggest that an 88% SpO FUNDING: ZonMw, The Dutch Foundation for Asthma Prevention, the Spaarne Gasthuis and Amphia Hospital Research Funds, and the Dutch General Paediatrics Research Network of the Dutch Association for Paediatrics.